Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line

Chemotherapy

Volumn 44, Issue 2, 1998, Pages 129-134

  Fallo, Francesco ^a   Pilon, Catia ^b   Barzon, Luisa ^b   Pistorello, Matteo ^b   Pagotto, Uberto ^b   Altavilla, Giuseppe ^b   Boscaro, Marco ^b   Sonino, Nicoletta ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

Adrenal cancer; Apoptosis; NCI H295; Paclitaxel; Steroids

Indexed keywords

ALDOSTERONE; DNA FRAGMENT; HYDROCORTISONE; PACLITAXEL; STEROID; TESTOSTERONE;

ADRENAL CORTEX CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEROIDOGENESIS;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ALDOSTERONE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; CHROMATIN; CULTURE MEDIA, CONDITIONED; CYTOPLASM; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROCORTISONE; MICROSCOPY, ELECTRON; PACLITAXEL; TESTOSTERONE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031881541     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007104     Document Type: Article

References (28)

1. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhame B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-1201.
2. Wooten MD, King DK: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-3155.
3. Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M: Adrenocortical carcinoma: Experience in 45 patients. Oncology 1997;54:490-496.
4. Rowinsky EK, Wright M, Monserrat B, Lesser GJ, Donehower RC: Taxol: Pharmacology, metabolism, and clinical implications. Cancer Surv 1993;17:283-304.
5. Long HJ: Paclitaxel (Taxol): A novel anticancer chemotherapeutic drug. Mayo Clin Proc 1994;69:341-345.
6. Manfredi JJ, Horwitz SB: Taxol: An antimitotic agent with a new mechanism of action. Pharmacol Ther 1984;25:83-125.
7. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259.
8. Feuilloley M, Vaudry H: Role of cytoskeleton in adrenocortical cells. Endocr Rev 1996;17:269-288.
9. Gazdar AF, Oie HK, Shackleton H, Chen TR, TRiche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, LaRocca RV: Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 1990;50:5488-5496.
10. Rainey WE, Bird IM, Mason JI: The NCI-H295 cell line: A pluripotent model for human adrenocortical studies. Mol Cell Endocrinol 1994; 100:45-50.
11. Danesi R, Figg WD, Reed E, Myers CE: Paclitaxel (Taxol) inhibits isoprenylation, and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995;47:1106-1111.
12. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demes GW, Galloway DA: Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-79.
13. Mosmann T: Rapid colorimetric assay for cellular growth survival: Applications to proliferation and cytoxicity assays. J Immunol Methods 1983;65:55-63.
14. Lewicka S, Bige K, Weindel K, Winter J, Pies W, Vecsei P: Production of 21-deoxyaldosterone by rat adrenal tissue in vitro: Evidence for an alternative biosynthetic pathway of aldosterone. Acta Endocrinol 1990; 123:225-230.
15. Haak HR, van Seters AP, Moolenar AJ, Fleuren GJ: Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 1993;29A:1036-1038.
16. Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom J, Backlin K, Nygren P: P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. Anticancer Res 1994;14:1009-1016.
17. LaRocca RV, Stein CA, Danesi R, Jamis-Dow CA, Weiss GH, Myers CE: Suramin in adrenal cancer: Modulation of steroid hormone production, cytoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990;71:497-504.
18. Bates SA, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL, Fojo AT: Mitotane enhances cytoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinoma. J Clin Endocrinol Metab 1991;73:18-29.
19. Schteingart DE, Sinsheimer JE, Counsell RE; Abrams GD, McClellan N, Djanegara T, Hines J, Ruangwises N, Benitez R, Wotring LL: Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemother Pharmacol 1993;31:459-466.
20. Arbuck SG, Canetta R, Onetto N, Christian MC: Current dosage and schedule issues in the development of paclitaxel (Taxol®). Semin Oncol 1993;20(Suppl3):31-39.
21. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB: Cytotoxic studies of paclitaxel (Taxol®) in human tumor cell lines. Br J Cancer 1993;68:1104-1109.
22. Ain KB, Tofiq S, Taylor K: Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1996;81:3650-3653.
23. Rowinsky EK, Donehower RC: The clinical pharmacology of paclitaxel (Taxol®). Semin Oncol 1993; 20(Suppl 2):16-25.
24. Schwartzman RA, Cidlowski JA: Apoptosis: The biochemistry and molecular biology of programmed cell death. Endocr Rev 1993;14: 133-151.
25. Kerr JFR, Winterford CM, Harmon BV: Morphological criteria for identifying apoptosis; in Celis JE (ed): Cell Biology. A Laboratory Handbook. San Diego, Academic Press, 1994, vol 1, pp 319-329.
26. CIP1/SDI1 and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. J Clin Invest 1996;97:1723-1731.
27. Wolkersdörfer GW, Ehrhart-Borstein M, Brauer S, Marx C, Scherbaum WA, Bornstein SR: Differential regulation of apoptosis in the normal human adrenal gland. J Clin Endocrinol Metab 1996;81:4129-4136.
28. Rainey WE, Kramer RE, Mason JI, Shay JW: The effect of taxol, a microtubule-stabilizing drug, on steroidogenic cells. J Cell Physiol 1985; 123:17-24.